Co-Amoxiclav Dosing and Duration for Acute Sinusitis
For acute bacterial sinusitis in adults, use high-dose amoxicillin-clavulanate (875 mg/125 mg twice daily) for 10-14 days, or consider 5-7 days in uncomplicated cases without risk factors. 1, 2
Adult Dosing
Standard Recommendation
- High-dose amoxicillin-clavulanate: 875 mg/125 mg twice daily (not to exceed 2 g every 12 hours) 1
- This formulation provides 90 mg/kg amoxicillin and 6.4 mg/kg clavulanate in adults
- High-dose formulation is preferred as first-line therapy when co-amoxiclav is chosen, particularly in regions with high antibiotic resistance 1
Duration of Treatment
- 10-14 days is the standard duration 1
- Some guidelines support 7-10 days as adequate 2
- 5-day courses may be appropriate for uncomplicated cases in patients without risk factors (no recurrent sinusitis, no previous sinus surgery, not attending daycare) 3
- Continue treatment until the patient is symptomatically improved for 7 days 1
Pediatric Dosing (Ages 3 months to 18 years)
For Children with Risk Factors
High-dose amoxicillin-clavulanate: 80-90 mg/kg/day of amoxicillin component with 6.4 mg/kg/day clavulanate in 2 divided doses (maximum 2 g per dose) 4
Risk factors include:
- Age younger than 2 years
- Attending child care
- Recent antibiotic use (within 30 days)
- Moderate to severe illness
For Children Without Risk Factors (Age ≥2 years)
- Standard-dose amoxicillin (45 mg/kg/day) is preferred over co-amoxiclav 4
- If co-amoxiclav is used: 45 mg/kg/day of amoxicillin component
Pediatric Duration
- 10-14 days is recommended, though optimal duration has not been systematically studied 4
Clinical Decision Algorithm
Assess for treatment response at 3-5 days:
- If improving: Continue treatment to complete 10-14 day course (or 7 days if using shorter duration protocol) 1
- If not improving: Switch to alternative antibiotic or consider complications 1
For partial response at end of first course:
- Continue treatment for another 10-14 days 1
For poor response (little/no improvement):
- Consider broader-spectrum coverage or evaluate for complications 1
Important Evidence-Based Considerations
Recent High-Quality Research Findings
Standard-dose amoxicillin alone may be equally effective with fewer adverse events in uncomplicated cases. A 2026 observational study of 234,608 adults found no difference in treatment failure between amoxicillin-clavulanate and amoxicillin alone (3.0% vs 3.1%), but amoxicillin-clavulanate had higher rates of yeast infections (1.1% vs 0.8%) and C. difficile infections (0.04% vs 0.02%) 5. Similar findings were observed in pediatric populations 6.
High-dose vs standard-dose co-amoxiclav: Two randomized trials found no benefit of high-dose (2000 mg amoxicillin component) over standard-dose (875 mg) co-amoxiclav in adults 7, 8. However, guidelines still recommend high-dose formulations based on resistance patterns 1.
Common Pitfalls to Avoid
Overprescribing duration: Most prescriptions exceed guideline-recommended durations; 75% of first-line agents are prescribed for >7 days when shorter courses may suffice 9
Inappropriate first-line use: Co-amoxiclav should be reserved for:
Not considering plain amoxicillin first: Current evidence suggests amoxicillin alone may be preferable for uncomplicated acute sinusitis in both adults and children, with lower adverse event rates 5, 6
Monitoring and Follow-Up
- Instruct patients to report if symptoms worsen (especially headache, high fever, visual changes) or fail to improve within 3-5 days 1
- Treatment failure requiring emergency department or inpatient care is rare (0.01-0.03%) 5, 6
- Diarrhea is the most common adverse event (12.9% protocol-defined diarrhea in pediatric studies) 10
Special Populations
Patients with penicillin allergy: Second- and third-generation cephalosporins carry minimal cross-reactivity risk and can be used safely 4
Pregnant women: Category B; use only if clearly needed 10
Nursing mothers: Excreted in breast milk; use with caution 10